Invention Grant
US07972775B2 Method of risk management for patients undergoing Natalizumab treatment
有权
接受那他珠单抗治疗的患者的风险管理方法
- Patent Title: Method of risk management for patients undergoing Natalizumab treatment
- Patent Title (中): 接受那他珠单抗治疗的患者的风险管理方法
-
Application No.: US11885615Application Date: 2006-02-24
-
Publication No.: US07972775B2Publication Date: 2011-07-05
- Inventor: Keith H. Rubin , Steven Glazer
- Applicant: Keith H. Rubin , Steven Glazer
- Applicant Address: US NY New York
- Assignee: Seedlings Life Science Ventures, LLC
- Current Assignee: Seedlings Life Science Ventures, LLC
- Current Assignee Address: US NY New York
- Agent Arthur Z. Bookstein
- International Application: PCT/US2006/006723 WO 20060224
- International Announcement: WO2006/112951 WO 20061026
- Main IPC: C12Q1/70
- IPC: C12Q1/70
Abstract:
Progressive multifocal leukoencephalopathy (PML) has been identified in patients taking natalizumab (NMAB) for the treatment of multiple sclerosis (MS). This patent application provides a novel method of patient screening and monitoring intended to decrease the risk of PML and other opportunistic central nervous system (CNS) diseases in patients undergoing MS therapy with NMAB, and proposes a novel method of screening and monitoring intended to decrease the risk of opportunistic disease processes of the CNS during the treatment of other medical disorders with NMAB.
Public/Granted literature
- US20090216107A1 Method of Risk Management for Patients Undergoing Natalizumab Treatment Public/Granted day:2009-08-27
Information query
